The IPO provides substantial capital to fund clinical-stage catalysts through 2027-2028 catalysts: Phase 3 STOP-HAE topline (onvuzosiran) expected end of 2027, and Phase 2 renal/PNH data (agazisiran) mid-2027. AbbVie's concurrent $89M private placement signals strategic validation. Monitor enrollment progress and any early clinical data readouts.
Executive Summary
ADARx Pharmaceuticals priced its initial public offering of 26,250,000 shares at $17.00 per share, raising $446.25 million in gross proceeds ($415.0 million net to the company before expenses). The offering was upsized from the 21,875,000-share range in the preliminary prospectus. Concurrently, AbbVie Inc. will purchase 5,233,264 shares in a private placement at the same price for approximately $89.0 million, resulting in AbbVie owning ~4.9% of the post-offering company. Total pro forma cash, cash equivalents, and short-term investments will be approximately $924.3 million, which management expects to fund operations into 2030.
Key Financial Metrics
Key Facts
- IPO of 26,250,000 shares priced at $17.00 per share, upsized from the 21,875,000-share preliminary range
- Gross proceeds of $446.25 million; net proceeds to company of approximately $415.0 million before expenses
- Underwriters granted a 30-day option to purchase up to 3,937,500 additional shares
- Concurrent private placement: AbbVie Inc. to purchase 5,233,264 shares at $17.00/share for ~$89.0 million, resulting in ~4.9% ownership post-closing
- Total pro forma cash, cash equivalents, and short-term investments of ~$924.3 million
- Pro forma shares outstanding immediately after offering and private placement: 106,801,325 shares (110,738,825 if underwriters' option exercised)
- Net proceeds allocated to advance pipeline: ~$180M for agazisiran, ~$65M for onvuzosiran, ~$80M for ADX-626, ~$25M for ADX-077, ~$20M for ADX-199
- Company expects existing cash and IPO/private placement proceeds to fund operations into 2030
- Company has three clinical-stage programs (agazisiran, onvuzosiran, ADX-626) and two advanced preclinical programs (ADX-077, ADX-199)
- AbbVie collaboration with AbbVie provided $335M upfront; eligible for up to $385M in option payments and up to $7.45B in milestones plus tiered royalties
Financial Impact
IPO raised $446.25M gross / ~$415.0M net; concurrent private placement adds ~$89.0M; total pro forma cash ~$924.3M. Net loss for H1 2026 was $48.4M, accumulated deficit $269.1M as of June 30, 2026.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; all programs in early-to-mid-stage development
- Phase 3 STOP-HAE trial (onvuzosiran) topline data expected end of 2027; risk of failure in pivotal trial
- Dilution: new investors paid $17.00/share vs existing stockholders' weighted-average $4.70; immediate dilution of $11.36 per share
- Need for substantial additional funding beyond 2030; risk of further dilution if additional capital needed
- Intellectual property risk: third-party patents may be alleged to cover onvuzosiran or GalNAc conjugation technology
- Reliance on third-party manufacturers; no long-term supply agreements in place
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-403094 |
| Document: 0001193125-26-403094-index-headers.html | 0001193125-26-403094 |
| Document: 0001193125-26-403094-index.html | 0001193125-26-403094 |
| Document: 0001193125-26-403094.txt | 0001193125-26-403094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $17.63 (−0.00%) |
Oct 5, 2026 21d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $17.63 (−5.11%) |
Oct 2, 2026 24d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $17.63 (−7.45%) |
Oct 1, 2026 25d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.63 (−3.40%) |
Oct 1, 2026 25d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.63 (−3.40%) |
Sep 30, 2026 26d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $17.63 (−9.77%) |
Sep 29, 2026 26d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $17.63 (−11.58%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $17.63 (−12.24%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.63 (−8.89%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.63 (−8.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers